| Bioactivity | DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT)[1][2][3][4]. | ||||||
| In Vivo | 177Lu-DOTATATE shows excellent antitumor effects in rats[1]. | ||||||
| Name | DOTATATE acetate | ||||||
| CAS | 177943-89-4 | ||||||
| Shortening | {D-Phe}-CY-{D-Trp}-KTCT (Disulfide bridge:Cys2-Cys7) | ||||||
| Formula | C65H90N14O19S2.xC2H4O2 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
||||||
| Reference | [1]. Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. [2]. Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. [3]. Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. [4]. Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. |
DOTATATE acetate
CAS: 177943-89-4 F: C65H90N14O19S2.xC2H4O2 W:
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.